COLORADO SPRINGS, Colo., Nov. 07, 2016 -- The Spectranetics Corporation (NASDAQ:SPNC), (“the Company”) today announced that company management will be attending three upcoming investor conferences.
On November 16th, 2016, the Company will attend the Stifel Healthcare Conference at the Lotte New York Palace Hotel. The fireside chat will begin at 8:45 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/stifel5/spnc.
On November 17th, 2016, the Company will attend the Canaccord Genuity Medical Technologies & Diagnostics Forum. The fireside chat will begin at 10 am Eastern Standard Time and can be accessed via the live webcast at http://wsw.com/webcast/canaccord24/spnc.
Additionally, on November 30th, 2016, the Company will attend the 28th Annual Piper Jaffray Healthcare Conference. Webcasting details will be available two weeks prior to the event.
Access to each of the three webcasts will also be available in the Events section of the Investor Relations website at http://www.spectranetics.com/investor-relations/investor-events.
About Spectranetics
The Spectranetics Corporation develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.
The Company's Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt scoring balloon used in both peripheral and coronary procedures, and the Stellarex drug-coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.
The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.
For more information, visit www.spectranetics.com.
Investor Relations Contacts Zach Stassen Sr. Director of Finance [email protected] (719) 447-2292 Michaella Gallina Director of Investor Relations [email protected] (719) 447-2417


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Instagram Outage Disrupts Thousands of U.S. Users
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



